Coherus Oncology Inc (CHRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 7,733 | 6,052 | 10,296 | 2,308 | 91,524 |
| Cost of Goods | 2,750 | 2,729 | 1,809 | 1,439 | 84,567 |
| Gross Profit | 4,983 | 3,323 | 8,487 | 869 | 6,957 |
| Operating Expenses | 51,117 | 50,908 | 48,922 | 69,095 | 76,429 |
| Operating Income | -45,384 | -46,856 | -39,626 | -67,787 | -68,905 |
| Interest Expense | 727 | 2,827 | 4,062 | 3,118 | 10,619 |
| Other Income | 1,203 | 2,084 | -11,163 | 2,869 | -129 |
| Pre-tax Income | -44,908 | -47,599 | -54,851 | -68,036 | -79,653 |
| Net Income Continuous | -44,908 | -47,599 | -54,851 | -68,036 | -79,653 |
| Net Income Discontinuous | -5,788 | 36,848 | 41,930 | 170,911 | N/A |
| Net Income | $-50,696 | $-10,751 | $-12,921 | $102,875 | $-79,653 |
| EPS Basic Total Ops | -0.46 | -0.09 | -0.11 | 0.91 | -0.67 |
| EPS Basic Continuous Ops | -0.39 | -0.41 | -0.48 | -0.60 | -0.67 |
| EPS Basic Discontinuous Ops | -0.08 | 0.32 | 0.37 | 1.52 | N/A |
| EPS Diluted Total Ops | -0.46 | -0.09 | -0.11 | 0.91 | -0.67 |
| EPS Diluted Continuous Ops | -0.39 | -0.41 | -0.48 | -0.60 | -0.67 |
| EPS Diluted Discontinuous Ops | -0.08 | 0.32 | 0.37 | 1.52 | N/A |
| EPS Diluted Before Non-Recurring Items | -0.44 | -0.09 | -0.20 | -0.38 | N/A |
| EBITDA(a) | $-44,351 | $-45,307 | $-38,439 | $-66,280 | $-67,842 |